Endogenous TGF-β1 inhibits the growth and metastatic dissemination of rat oral carcinoma cell lines but enhances local bone resorption

Journal of Oral Pathology and Medicine

Volumn 29, Issue 5, 2000, Pages 232-240

  Davies, Maria ^a,b   Prime, Stephen S ^a   Stone, Andrea M ^a   Huntley, Suzy P ^a   Eveson, John W ^a   Paterson, Ian C ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b BRISTOL DENTAL HOSPITAL   (United Kingdom)

Author keywords

Bone resorption; Differentiation; Keratinocyte; Metastasis; TGF

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA;

ANIMAL; ARTICLE; CANCER TRANSPLANTATION; CELL CULTURE; CELL DIVISION; CELL LINE; GENETIC TRANSFECTION; GENETICS; METASTASIS; MOUSE; MOUTH TUMOR; NUDE MOUSE; OSTEOLYSIS; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RAT;

ANIMALS; BONE RESORPTION; CELL DIVISION; CELL LINE, TRANSFORMED; MICE; MICE, NUDE; MOUTH NEOPLASMS; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; RATS; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA; TUMOR CELLS, CULTURED;

EID: 0033624954     PISSN: 09042512     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0714.2000.290507.x     Document Type: Article

References (37)

1. Roberts AB, Sporn MB. The transforming growth factors. In: Roberts AB, Sporn MB, eds. Peptide growth factors and their receptors I. Berlin: Springer Verlag, 1990; 419-72.
2. Massague J. The transforming growth factor-β family. Annu Rev Cell Biol 1990; 6: 597-641.
3. Lyons RM, Moses HL. Transforming growth factors and the regulation of cell proliferation. Eur J Biochem 1990; 187: 467-73.
4. Roberts AB. Molecular and cell biology of TGF-β. Miner Electrolyte Metab 1998; 24: 111-9.
5. Fynan TM, Reiss M. Resistance to inhibition of cell growth by transforming growth factor-β and its role in oncogenesis. Crit Rev Oncog 1993; 4: 493-540.
6. Hu PP-C, Datto MB, Wang X-F. Molecular mechanisms of transforming growth factor-β signalling. Endocr Rev 1998; 19: 349-63.
7. Steiner MS, Barrack ER. Transforming growth factor-β1 overproduction in prostate cancer: effects on growth in vivo and in vitro. Mol Endocrinol 1992; 6: 15-25.
8. Arrick BA, Lopez AR, Elfman F, Ebner R, Damsky CH, Derynck R. Altered metabolic and adhesive properties and increased tumorigenesis associated with increased expression of transforming growth factor-beta-1. J Cell Biol 1992; 118: 715-26.
9. Arteaga CL, Dugger TC, Winnier AR, Forbes JT. Evidence for a positive role of transforming growth factor-β in human breast cancer cell tumorigenesis. J Cell Biochem 1993; 17G: 187-93.
10. Chang H-L, Gillett N, Figari I, Lopez AR, Palladino MA, Derynck R. Increased transforming growth factor-β expression inhibits cell proliferation in vitro, yet increases tumorigenicity and tumor growth of meth A sarcoma cells. Cancer Res 1993; 53: 4391-8.
11. Fitzpatrick DR, Bielefeldt-Ohmann H, Himbeck RP, Jarnicki AG, Marzo AL, Robinson BWS. Transforming growth factor-β: antisense RNA-mediated inhibition affects anchorage-independent growth, tumorigenicity, and tumour-infiltrating T-cells in malignant mesothelioma. Growth Factors 1994; 11: 29-44.
12. Huang F, Newman E, Theodorescu D, Kerbel RS, Friedman E. Transforming growth factor-β1 (TGF-β1) is an autocrine positive regulator of colon carcinoma U9 cells in vivo as shown by transfection of a TGF-β1 antisense expression plasmid. Cell Growth Differ 1995; 6: 1635-42.
13. Park JA, Wang E, Kurt RA, Scluter SF, Hersh EM, Akporiaye ET. Expression of an antisense transforming growth factor-β1 transgene reduces tumorigenicity of EMT6 mammary tumour cells. Cancer Gene Ther 1997; 4: 42-50.
14. Wu S, Theordorescu D, Kerbel RS, et al. TGF-β1 is an autocrine-negative regulator of human colon FET cells in vivo as revealed by transfection of an antisense expression vector. J Cell Biol 1992; 116: 187-96.
15. Wu SP, Sun L-Z, Willson JKV, Humphrey L, Kerbel R, Brattain MG. Repression of autocrine transforming growth factor-β1 and -β2 in quiescent CBS colon carcinoma cells leads to progression of tumorigenic properties. Cell Growth Differ 1993; 4: 115-23.
16. Pierce DF, Gorska AE, Chytil A, et al. Mammary tumor suppression by transforming growth factor-β1 transgene expression. Proc Natl Acad Sci USA 1995; 92: 4254-8.
17. Davies M, Prime SS, Stone AM, et al. Overexpression of autocrine TGF-β1 suppresses the growth of spindle epithelial cells in vitro and in vivo in the rat 4NQO model of oral carcinogenesis. Int Cancer 1997; 73: 68-74.
18. Glick AB, Kulkarni AB, Tennenbaum T, et al. Loss of expression of transforming growth factor-β in skin and skin tumours is associated with hyperproliferation and a high risk for malignant conversion. Proc Natl Acad Sci USA 1993; 90: 6076-80.
19. Fahey MS, Paterson IC, Stone A, et al. Dysregulation of autocrine TGF-β isoform production and ligand responses in human tumour-derived and Ha-ras-transfected keratinocytes and fibroblasts. Br J Cancer 1996; 74: 1074-80.
20. null mice is prognostic for a high risk of malignant conversion. Cancer Res 1994; 54: 5831-6.
21. Glick AB, Lee MM, Darwiche N, Kulkarni AB, Karlsson S, Yuspa SH. Targeted deletion of the TGF-β1 gene causes rapid progression to squamous cell carcinoma. Genes Dev 1994; 8: 2429-40.
22. Cui W, Fowlis DJ, Cousins FM, et al. Concerted action of TGF-beta 1 and its type II receptor in control of epidermal homeostasis in transgenic mice. Genes Dev 1995; 9: 945-55.
23. Fowlis DJ, Cui W, Johnson SA, Balmain A, Akhurst RJ. Altered epidermal cell growth control in vivo by inducible expression of transforming growth factor-β1 in the skin of transgenic mice. Cell Growth Differ 1996; 7: 679-87.
24. Cui W, Fowlis DJ, Bryson S, et al. TGF-β1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice. Cell 1996; 86; 531-42.
25. Miettinen PJ, Ebner R, Lopez AR, Derynck R. TGF-β induced transdifferentiation of mammary epithelial cells to mesenchymal cells: involvement of type I receptors. J Cell Biol 1994; 127: 2021-36.
26. 1 induces an epithelial-mesenchymal transdifferentiation and a spindle tumoral phenotype. Cell Growth Differ 1995; 6: 1027-35.
27. Kitagawa K, Murata A, Matsuura N, et al. Epithelial-mesenchymal transformation of a newly established cell line from ovarian adenosarcoma by transforming growth factor-β1. Int J Cancer 1996; 66: 91-7.
28. Oft M, Peli J, Rudaz C, Schwartz H, Beug H, Reichmann E. TGF-β1 and Ha-ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumour cells. Genes Dev 1996; 10: 2462-77.
29. Portella G, Cumming SA, Liddell J, et al. Transforming growth factor-β is essential for spindle cell conversion of mouse skin carcinoma in vivo: implications for tumour invasion. Cell Growth Differ 1998; 9: 393-404.
30. Patel V, Poulopoulos AK, Levan G, Game SM, Eveson JW, Prime SS. Loss of expression of basement membrane proteins reflects anomalies of chromosomes 3 and 12 in the rat 4-nitroquinoline-N-oxide model of oral carcinogenesis. Carcinogenesis 1995; 16: 17-23.
31. Davies M, Paterson, IC, Stone A, et al. Loss of differentiation of 4NQO-induced rat malignant oral keratinocytes correlates with metastatic dissemination and is associated with a reduced cellular response to TGF-β1 and an altered receptor profile. J Oral Pathol Med 1999; 28: 397-405.
32. Game SM, Stone A, Scully C, Prime SS. Tumour progression in experimental oral carcinogenesis is associated with changes in EGF and TGF-β receptor expression and altered responses to these growth factors. Carcinogenesis 1990; 11: 965-73.
33. Game SM, Stone A, Matthews JB, Scully C, Prime SS. Differentiation of malignant oral rat keratinocyte reflects changes in EGF and TGF-β receptor expression but not growth factor dependence. Carcinogenesis 1991; 12: 409-16.
34. Yin JJ, Selander K, Chirgwin JM, et al. TGF-β signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest 1999; 103: 197-206.
35. Oft M, Heider K-H, Beug H. TGFß signaling is necessary for carcinoma cell invasiveness and metastasis. Curr Biol 1998; 8: 1243-52.
36. Suzui M, Yoshimi N, Tanaka T, Mori H. Infrequent Ha-ras mutations and absence of Ki-ras, N-ras, and p53 mutations in 4-nitroquinoline 1-oxide-induced rat oral lesions. Mol Carcinog 1995; 14: 294-8.
37. Yuan B, Heniford BW, Ackermann DM, Hawkins BL, Hendler FJ. Harvey Ras (H-ras) point mutations are induced by 4-nitroquinoline-1-oxide in murine oral squamous epithelia, while squamous cell carcinomas and loss of heterozygosity occur without additional exposure. Cancer Res 1994; 54: 5310-7.